These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38174446)

  • 1. Drug Repositioning of Pioglitazone in Management and Improving the Cognitive Function among the Patients With Mild to Moderate Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Basutkar RS; Sudarsan P; Robin SM; Bhaskar V; Viswanathan B; Sivasankaran P
    Neurol India; 2023; 71(6):1132-1141. PubMed ID: 38174446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donepezil for dementia due to Alzheimer's disease.
    Birks JS; Harvey RJ
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
    Burns DK; Alexander RC; Welsh-Bohmer KA; Culp M; Chiang C; O'Neil J; Evans RM; Harrigan P; Plassman BL; Burke JR; Wu J; Lutz MW; Haneline S; Schwarz AJ; Schneider LS; Yaffe K; Saunders AM; Ratti E;
    Lancet Neurol; 2021 Jul; 20(7):537-547. PubMed ID: 34146512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
    Farina N; Llewellyn D; Isaac MG; Tabet N
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD002854. PubMed ID: 28128435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivastigmine for Alzheimer's disease.
    Birks JS; Grimley Evans J
    Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of hypoglycemic drugs in improving cognitive function in patients with Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis.
    Wang XC; Chu CL; Li HC; Lu K; Liu CJ; Cai YF; Quan SJ; Zhang SJ
    Front Neurol; 2022; 13():1018027. PubMed ID: 36530613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
    Sampson EL; Jenagaratnam L; McShane R
    Cochrane Database Syst Rev; 2012 May; 5(5):CD005380. PubMed ID: 22592705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metrifonate for Alzheimer's disease.
    López-Arrieta JM; Schneider L
    Cochrane Database Syst Rev; 2006 Apr; (2):CD003155. PubMed ID: 16625573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Souvenaid for Alzheimer's disease.
    Burckhardt M; Watzke S; Wienke A; Langer G; Fink A
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD011679. PubMed ID: 33320335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials.
    Abushouk AI; Elmaraezy A; Aglan A; Salama R; Fouda S; Fouda R; AlSafadi AM
    BMC Neurol; 2017 Apr; 17(1):66. PubMed ID: 28376794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
    De Jesus Moreno Moreno M
    Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selegiline for Alzheimer's disease.
    Birks J; Flicker L
    Cochrane Database Syst Rev; 2003; (1):CD000442. PubMed ID: 12535396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scope of new formulation approaches in the repurposing of pioglitazone for the management of Alzheimer's disease.
    Jojo GM; Kuppusamy G
    J Clin Pharm Ther; 2019 Jun; 44(3):337-348. PubMed ID: 30738020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galantamine for Alzheimer's disease and mild cognitive impairment.
    Loy C; Schneider L
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD001747. PubMed ID: 16437436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer's disease and amnestic mild cognitive impairment: a systematic review and meta-analysis.
    Liu J; Wang LN; Jia JP
    Drugs Aging; 2015 Jan; 32(1):57-65. PubMed ID: 25504005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omega-3 fatty acids for the treatment of dementia.
    Burckhardt M; Herke M; Wustmann T; Watzke S; Langer G; Fink A
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD009002. PubMed ID: 27063583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galantamine for vascular cognitive impairment.
    Birks J; Craig D
    Cochrane Database Syst Rev; 2006 Jan; (4):CD004746. PubMed ID: 23862185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.